A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504678-39-00

Acronym

CXXB750A12201

Enrollment

424

Registered

2024-03-04

Start date

2024-03-13

Completion date

2024-11-08

Last updated

2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Change in log NT-proBNP from baseline to Week 16

Detailed description

Change in log NT-proBNP from baseline to Week 16, Adverse events, safety laboratory parameters, and vital signs from baseline to end of study (EOS)

Interventions

DRUGLISINOPRIL

DRUGXXB750

DRUGAZILSARTAN MEDOXOMIL

DRUGCANDESARTAN

DRUGBENAZEPRIL

DRUGTRANDOLAPRIL

DRUGFOSINOPRIL

DRUGPERINDOPRIL

DRUGMOEXIPRIL

DRUGQUINAPRIL

DRUGCAPTOPRIL

DRUGEPROSARTAN

DRUGRAMIPRIL

DRUGIRBESARTAN

DRUGVALSARTAN AND SACUBITRIL

DRUGZOFENOPRIL

DRUGCILAZAPRIL

DRUGDELAPRIL

DRUGOLMESARTAN MEDOXOMIL

DRUGIMIDAPRIL

DRUG0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection

DRUGENALAPRIL

DRUGTELMISARTAN

DRUGVALSARTAN

DRUGLOSARTAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in log NT-proBNP from baseline to Week 16	—

Secondary

Measure	Time frame
Change in log NT-proBNP from baseline to Week 16, Adverse events, safety laboratory parameters, and vital signs from baseline to end of study (EOS)	—

Countries

Bulgaria, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Portugal, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026